glutamic acid has been researched along with ibogaine in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Scallet, AC; Ye, X | 1 |
Elisabetsky, E; Emanuelli, T; Leal, MB; Porciúncula, LD; Souza, DO | 1 |
Molliver, ME; O'Hearn, E | 1 |
Vastag, B | 1 |
Arena, E; Aricò, G; Bertucci, C; Campisi, A; Parenti, C; Pistolozzi, M; Prezzavento, O; Ronsisvalle, G; Ronsisvalle, S; Scoto, GM; Vanella, A | 1 |
1 review(s) available for glutamic acid and ibogaine
Article | Year |
---|---|
Excitotoxic mechanisms of neurodegeneration in transmissible spongiform encephalopathies.
Topics: Animals; Brain; Cricetinae; Glutamic Acid; Humans; Hypothalamus; Ibogaine; Kainic Acid; Mice; N-Methylaspartate; Nerve Degeneration; Neurotoxins; Prion Diseases | 1997 |
4 other study(ies) available for glutamic acid and ibogaine
Article | Year |
---|---|
Ibogaine alters synaptosomal and glial glutamate release and uptake.
Topics: Animals; Astrocytes; Calcium; Cells, Cultured; Cerebral Cortex; Excitatory Amino Acid Antagonists; Glutamic Acid; Ibogaine; Male; Mice; Mice, Inbred Strains; Rats; Rats, Wistar; Synaptosomes; Tetrodotoxin; Tritium; Veratridine | 2001 |
Administration of a non-NMDA antagonist, GYKI 52466, increases excitotoxic Purkinje cell degeneration caused by ibogaine.
Topics: Animals; Benzodiazepines; Dose-Response Relationship, Drug; Drug Synergism; Excitatory Amino Acid Antagonists; Glutamic Acid; Ibogaine; Male; Nerve Degeneration; Neurotoxins; Olivary Nucleus; Purkinje Cells; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Synapses; Synaptic Transmission; Up-Regulation | 2004 |
Addiction research. Ibogaine therapy: a 'vast, uncontrolled experiment'.
Topics: Animals; Brain; Clinical Trials as Topic; Dopamine; Glial Cell Line-Derived Neurotrophic Factor; Glutamic Acid; Hallucinations; Hallucinogens; Humans; Ibogaine; Nerve Growth Factors; Receptors, Nicotinic; Receptors, Opioid; Selective Serotonin Reuptake Inhibitors; Serotonin; Substance-Related Disorders | 2005 |
Synthesis and resolution of cis-(+/-)-methyl (1R,2S/1S,2R)-2-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-(4-methylphenyl)cyclopropanecarboxylate [(+/-)-PPCC)]: new sigma receptor ligands with neuroprotective effect.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Non-Narcotic; Animals; Astrocytes; Cells, Cultured; Cyclopropanes; Drug Interactions; Glutamic Acid; Glutathione; GTP-Binding Proteins; Ibogaine; Ligands; Neuroprotective Agents; Oxidative Stress; Pentazocine; Piperidines; Protein Glutamine gamma Glutamyltransferase 2; Rats; Reactive Oxygen Species; Receptors, Opioid, kappa; Receptors, sigma; Stereoisomerism; Structure-Activity Relationship; Transglutaminases | 2010 |